We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In ...
Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...
2d
Assenagon Asset Management S.A. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 62.2% in the ...
Mike Morin: We’re very proud to represent Sarepta Therapeutics, an innovative biotechnology company that focuses exclusively ...
Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...
6d
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating yesterday.Stay Ahead of the ...
'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, ...
Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and ...
January 13, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback